Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray

Proteomics - Clinical Applications

Volumn 4, Issue 3, 2010, Pages 285-294

  Oyelaran, Oyindasola ^a   Gildersleeve, Jeffrey C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody; Antigen array; Glycan array; Keyhole limpet hemocyanin; Tumor associated carbohydrate antigen

Indexed keywords

BIOLOGICAL MARKER; CARBOHYDRATE ANTIGEN; GANGLIOSIDE GM3; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; SIALYL LEWIS X ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; MALE; MICROARRAY ANALYSIS; NORMAL HUMAN; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; ANTIBODIES; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CARBOHYDRATES; HEMOCYANIN; HUMANS; IMMUNE SERA; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MICROARRAY ANALYSIS; YOUNG ADULT;

ANIMALIA;

EID: 77951819743     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900130     Document Type: Article

References (53)

1. Harris, J.R., Markl, J., Keyhole limpet hemocyanin (KLH): a biomedical review. Micron 1999, 30, 597-623.
2. Helling, F., Zhang, S., Shang, A., Adluri, S. et al., GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 1995, 55, 2783.
3. Gilewski, T.A., Ragupathi, G., Dickler, M., Powell, S. et al., Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin. Cancer Res. 2007, 13, 2977-2985.
4. Slovin, S.F., Ragupathi, G., Musselli, C., Olkiewicz, K. et al., Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-Serine/Threonine conjugate vaccine. J. Clin. Oncol. 2003, 21, 4292-4298.
5. Schumacher, K., Keyhole limpet hemocyanin (KLH) conjugate vaccines as novel therapeutic tools in malignant disorders. J. Cancer Res. Clin. Oncol. 2001, 127, R1-2.
6. Spatz, M., Eibl, N., Hink, S., Wolf, H.M. et al., Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells. Cell. Immunol. 2003, 221, 15-26.
7. Olsson, C.A., Chute, R., Rao, C.N., Immunologic reduction of bladder cancer recurrence rate. J. Urol. 1974, 111, 173-176.
8. Lamm, D.L., Dehaven, J.I., Riggs, D.R., Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur. Urol. 2000, 37, 41-44.
9. Jurincic-Winkler, C.D., Metz, K.A., Beuth, J., Klippel, K.F., Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study. Eur. Urol. 2000, 37, 45-49.
10. Grzych, J.M., Dissous, C., Capron, M., Torres, S. et al., Schistosoma mansoni shares a protective carbohydrate epitope with keyhole limpet hemocyanin. J. Exp. Med. 1987, 165, 865-878.
11. Zhang, S.L., CordonCardo, C., Zhang, H.S., Reuter, V.E. et al., Selection of tumor antigens as targets for immune attack using immunohistochemistry.1. Focus on gangliosides. Int. J. Cancer 1997, 73, 42-49.
12. Lamm, D.L., Laboratory and clinical experience with keyhole limpet hemocyanin (Immucothels) in superficial bladder cancer. J. Urol. Urogynäkol. 2003, 10, 18-21.
13. Riggs, D.R., Jackson, B., Vona-Davis, L., McFadden, D., In vitro anticancer effects of a novel immunostimulant: keyhole limpet hemocyanin. J. Surg. Res. 2002, 108, 279-284.
14. Riggs, D.R., Jackson, B.J., Vona-Davis, L., Nigam, A., McFadden, D.W., In vitro effects of keyhole limpet hemocyanin in breast and pancreatic cancer in regards to cell growth, cytokine production, and apoptosis. Am. J. Surg. 2005, 189, 680-684.
15. McFadden, D.W., Riggs, D.R., Jackson, B.J., Vona-Davis, L., Keyhole limpet hemocyanin, a novel immune stimulant with promising anticancer activity in Barrett's esophageal adenocarcinoma. Am. J. Surg. 2003, 186, 552-555.
16. Presicce, P., Taddeo, A., Conti, A., Villa, M.L., Bella, S.D., Keyhole limpet hemocyanin induces the activation and maturation of human dendritic cells through the involvement of mannose receptor. Mol. Immunol. 2008, 45, 1136-1145.
17. Lamm, D.L., Dehaven, J.I., Riggs, D.R., Ebert, R.F., Immunotherapy of murine bladder-cancer with keyhole limpet hemocyanin (Klh). J. Urol. 1993, 149, 648-652.
18. Tzianabos, A.O., Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function. Clin. Microbiol. Rev. 2000, 13, 523-533.
19. Wirguin, I., Suturkovamilosevic, L., Briani, C., Latov, N., Keyhole limpet hemocyanin contains Gal(Beta-1-3)-Galnac determinants that are cross-reactive with the T-antigen. Cancer Immunol. Immunother. 1995, 40, 307-310.
20. May, R.J., Beenhouwer, D.O., Scharff, M.D., Antibodies to Keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development. J. Immunol. 2003, 171, 4905.
21. JurincicWinkler, C.D., VonderKammer, H., Beuth, J., Scheit, K.H., Klippel, K.F., Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma. Anticancer Res. 1996, 16, 2105-2110.
22. Van Kuik, J.A., Kamerling, J.P., Vliegenthart, J.F.G., in: Preaux, G., Lontie, R. (Eds.), Invertebrate Oxygen Carriers, Leuven University Press, Leuven 1990, pp. 157-163.
23. Park, S., Lee, M., Shin, I., Carbohydrate microarrays as powerful tools in studies of carbohydrate-mediated biological processes. Chem. Commun. 2008, 4389-4399.
24. Liang, P.-H., Wu, C.-Y., Greenberg, W.A., Wong, C.-H., Glycan arrays: biological and medical applications. Curr. Opin. Chem. Biol. 2008, 12, 86-92.
25. Oyelaran, O., Gildersleeve, J.C., Application of carbohydrate array technology to antigen discovery and vaccine development. Expert Rev. Vaccines 2007, 6, 957-969.
26. Paulson, J.C., Blixt, O., Collins, B.E., Sweet spots in functional glycomics. Nat. Chem. Biol. 2006, 2, 238-248.
27. Smith, T.P., Kennedy, S.L., Fleshner, M., Influence of age and physical activity on the primary in vivo antibody and T cell-mediated responses in men. J. Appl. Physiol. 2004, 97, 491-498.
28. Woodward, M.P., Young, W.W., Bloodgood, R.A., Detection of monoclonal antibodies specific for carbohydrate epitopes using periodate oxidation. J. Immunol. Methods 1985, 78, 143-153.
29. Oyelaran, O., McShane, L.M., Dodd, L., Gildersleeve, J.C., Profiling human serum antibodies with a carbohydrate antigen microarray. J. Proteome Res. 2009, 8, 4301-4310.
30. Lyng, H., Badiee, A., Svendsrud, D.H., Hovig, E. et al., Profound influence of microarray scanner characteristics on gene expression ratios: Analysis and procedure for correction. Biomed. Chromatogr. Genomics 2004, 5, doi: 10.1186/1471-2164-5-10.
31. Nicklas, W., Aluminum salts. Res. Immunol. 1992, 143, 489-494.
32. Lindblad, E.B., Aluminium adjuvants - in retrospect and prospect. Vaccine 2004, 22, 3658-3668.
33. Oyelaran, O.O., Li, Q., Farnsworth, D.F., Gildersleeve, J.C., Microarrays with varying carbohydrate density reveal distinct subpopulations of serum antibodies. J. Proteome Res. 2009, 8, 3529-3538.
34. Li, Q., Anver, M.R., Butcher, D.O., Gildersleeve, J.C., Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines. Mol. Cancer. Res. 2009, 8, 971-979.
35. Hsu, K.L., Gildersleeve, J.C., Mahal, L.K., A simple strategy for the creation of a recombinant lectin microarray. Mol. BioSyst. 2008, 4, 654-662.
36. Gildersleeve, J.C., Oyelaran, O., Simpson, J.T., Allred, B., Improved procedure for direct coupling of carbohydrates to proteins via reductive amination. Bioconjug. Chem. 2008, 19, 1485-1490.
37. Manimala, J.C., Roach, T.A., Li, Z., Gildersleeve, J.C., High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. Glycobiology 2007, 17, 17C-23C.
38. Manimala, J.C., Roach, T.A., Li, Z.T., Gildersleeve, J.C., High-throughput carbohydrate microarray analysis of 24 lectins. Angew. Chem. Int. Ed. Engl. 2006, 45, 3607-3610.
39. Manimala, J., Li, Z., Jain, A., VedBrat, S., Gildersleeve, J.C., Carbohydrate array analysis of anti-Tn antibodies and lectins reveals unexpected specificities: Implications for diagnostic and vaccine development. ChemBioChem 2005, 6, 2229-2241.
40. Li, Q., Anver, M.R., Li, Z., Butcher, D.O., Gildersleeve, J.C., GalNAca1-3Gal, a New prognostic marker for cervical cancer. Int. J. Cancer 2010, 126, 459-468.
41. Burke, G.P., Smith, K.A., Stocking, R.I., Ferm, M., McIntyre, O.R., Anti-keyhole limpet hemocyanin antibody in normal unsensitized individuals. J. Allergy Clin. Immunol. 1977, 59, 309-313.
42. Kurokawa, T., Wuhrer, M., Lochnit, G., Geyer, H. et al., Hemocyanin from the keyhole limpet Megathura crenulata (KLH) carries a novel type of N-glycans with Gal(beta1-6)Man-motifs. Eur. J. Biochem. 2002, 269, 5459-5473.
43. Kantelhardt, S.R., Wuhrer, M., Dennis, R.D., Doenhoff, M.J. et al., Fuc(alpha1->3)GalNAc-: the major antigenic motif of Schistosoma mansoni glycolipids implicated in infection sera and keyhole-limpet haemocyanin cross-reactivity. Biochem. J. 2002, 366, 217-223.
44. Wuhrer, M., Robijn, M.L., Koeleman, C.A., Balog, C.I. et al., A novel Gal(beta1-4)Gal(beta1-4)Fuc(alpha1-6)-core modification attached to the proximal N-acetylglucosamine of keyhole limpet haemocyanin (KLH) N-glycans. Biochem. J. 2004, 378, 625-632.
45. Ohyama, C., Glycosylation in bladder cancer. Int. J. Clin. Oncol. 2008, 13, 308-313.
46. Fuster, M.M., Esko, J.D., The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 2005, 5, 526-542.
47. Dube, D.H., Bertozzi, C.R., Glycans in cancer and inflammation. Potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 2005, 4, 477-488.
48. Loo, D., Pryer, N., Young, P., Liang, T. et al., The glycotopespecific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol. Cancer. Ther. 2007, 6, 856-865.
49. Amaya, S., Sasaki, M., Watanabe, Y., Tsui, W.M.S. et al., Expression of MUC1 and MUC2 and carbohydrate antigen Tn change during malignant transformation of biliary papillomatosis. Histopathology 2001, 38, 550-560.
50. Nores, G.A., Dohi, T., Taniguchi, M., Hakomori, S., Densitydependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. J. Immunol. 1987, 139, 3171-3176.
51. Saito, K., Fujii, Y., Kawakami, S., Hayashi, T. et al., Increased expression of sialyl-Lewis A correlates with poor survival in upper urinary tract urothelial cancer patients. Anticancer Res. 2003, 23, 3441-3446.
52. Amano, K., Hayashi, S., Kubota, T., Fujii, N., Yokota, S., Reactivities of Lewis antigen monoclonal antibodies with the lipopolysaccharides of Helicobacter pylori strains isolated from patients with gastroduodenal diseases in Japan. Clin. Diagn. Lab. Immunol. 1997, 4, 540-544.
53. Hecht, M.L., Rosental, B., Horlacher, T., Hershkovitz, O. et al., Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. J. Proteome Res. 2009, 8, 712-720.